Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · STAR

STAR

HealthcarePharmaceuticals & Biotechnology₹8831 cr market cap
₹982.30 ▲ +2.53% today As of 19 Nov 2026
52-week low ₹793.5552-week high ₹1235.10

-22.4% from the 52-week high · +20.7% above the low

Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka and currently employs 2,850 full-time employees. The company went IPO on 2000-02-03. The firm is focused on the development and manufacture of IP-led niche and pharmaceutical products. The firm operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.

The short version. STAR reported revenue of ₹1,430 crore for Sep 2026, up 17.1% from a year earlier. Net profit was ₹131 crore (up 2.3% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 29.0% in Sep 2026, up 2.18 points over 8 quarters.

1 · The price

How has the stock traded?

STAR trades 22.4% below its 52-week high and 20.7% above its 52-week low.

Change over period: —

1M-6.9%
3M+0.1%
6M-16.1%
1Y-0.8%

2 · The business

Is it growing?

Sales, year on year+17.1%

Sep 2026 revenue of ₹1,430 cr.

Profit, year on year+2.3%

Sep 2026 net profit of ₹131 cr.

Net margin9.2%

1.2 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue14301265132311951221112011901154
Net profit1311571272021281008288
Net margin %9.212.49.616.910.48.96.97.6
EPS (₹)14.1917.0213.7721.9313.8410.818.929.54

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue48594565405136883070331627523012
Net profit5563593-71-203-46026836325
Net margin %11.478.7-1.7-5.5-15.08.11.310.8
EPS (₹)60.34389.9-7.68-22.44-51.2529.934.0636.25

3 · The quality

How well does it turn capital into profit?

Return on equity was 17.9% in Mar 2026; debt to equity is 0.54.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %17.9140.8-3.3-9.2
Return on capital %21.021.212.67.1
EBITDA margin %20.920.014.513.3
Net margin %11.177.7-1.7-5.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.8%8.3%
Profit CAGR—15.7%
Debt to equity0.54
Interest cover4.7x
Current ratio1.25
P/E ratio14.3

4 · The owners

Who holds it, and are they adding?

Promoter holding29.0%

Up 2.18 pts over 8 quarters.

Foreign institutions27.98%

Down 0.5 pts over 8 quarters.

Domestic institutions15.51%

Down 1.41 pts over 8 quarters.

Mutual fund schemes17

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter26.8228.328.327.8627.8627.9127.9129.0+2.18
FII28.4828.3228.0228.5129.5228.6828.3927.98-0.5
DII16.9213.7213.312.9813.0214.4515.4115.51-1.41
Public27.7729.6530.3730.6429.5928.9528.2827.51-0.26

Mutual fund holdings · Oct 2026

17 schemes hold this stock

13 the month before.

  • quant Healthcare Fund8.79% of NAV
  • quant Multi Cap Fund2.11% of NAV
  • quant Small Cap Fund1.24% of NAV
  • Bandhan Small Cap Fund0.97% of NAV
  • Motilal Oswal Nifty Microcap 250 Index Fund0.87% of NAV
  • Motilal Oswal BSE Healthcare ETF0.44% of NAV
  • Bandhan BSE Healthcare Index Fund0.44% of NAV
  • ADITYA BIRLA SUN LIFE VALUE FUND0.28% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for STAR are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about STAR

What is the STAR share price?

STAR (STAR) last closed at ₹982.30, up 2.53% on the day. Its 52-week range is ₹793.55 to ₹1,235.10.

What is the market cap of STAR?

STAR has a market capitalisation of about ₹8,831 crore. Its price-to-earnings ratio is 14.3.

How are STAR's latest results?

STAR reported revenue of ₹1,430 crore for Sep 2026, up 17.1% from a year earlier. Net profit was ₹131 crore (up 2.3% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 29.0% in Sep 2026, up 2.18 points over 8 quarters.

Who owns STAR?

As of Sep 2026, shareholding was: Promoter 29.0%, FII 27.98%, DII 15.51%, Public 27.51%.

How many mutual funds hold STAR?

17 mutual fund schemes held STAR in October 2026. That compares with 13 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 22 Jul 2025 · Final Dividend - Rs. 4
  • 09 Sep 2024 · Final Dividend - Rs. 2.5
  • 04 Aug 2023 · Final Dividend - Rs. 1.5
  • 05 Aug 2021 · Final Dividend - Rs. 2.5
  • 24 Jul 2020 · Final Dividend - Rs. 2
  • 22 Aug 2019 · Interim Dividend - Rs. 12

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.